BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Acitretin and teratogenicity: Compliance with safety measures in women of childbearing potential

Active substance: acitretin

On a European level it is currently being discussed that the 2-year period of pregnancy prevention in patients of childbearing potential is possibly not sufficient and must therefore be extended to 3 years after end of treatment.

To the risk information - full text (available in German only)

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK